Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study

Abstract

No statistically significant difference in median overall survival in patients with advanced colorectal cancer treated with bevacizumab plus a combination therapy (arm A) and those treated with the combination only, without bevacizumab (arm B), was observed.